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Objective: The utility of a novel cardiovascular risk assessment and lipid disorders management software in a Lipid Clinic leading to improved 
clinical outcomes .
Background: CVD evaluator is an expert system written in visual basic 6 and dotnet, patented by USPO. The system computes the data from basic 
clinical information, lipid profile, if available emerging risk factors, advanced lipid profile including genetic risk factors to make specific diagnostic 
and therapeutic recommendations. It utilizes all published CV disease risk scoring systems (such as Framingham,Procam),published guidelines 
including NCEP,ITF,ADA,NKF. The diagnostic and therapatic recommendations are based on major studies and clinical trials which are cited in the 
reference section of the output .
Methods: We randomly retrieved the current records of 200 patients(100 with CHD )whose initial lipid management decision were aided by the 
system within 6 months of its implementation in Aug,2006 and compared their outcomes to 200 clinical profile matched control group managed by 
clinical cardiologists (Table 1)
The primary end point was the achievement of target LDL-C and nonHDL-C at any point.The safety endpoint included discontinuation of any 
medication for persistently elevated CPK or LFTs or rhabdomyolisis.The secondary endpoint was combined events of CV death,nonfatal MI,any 
revascularization. Fisher’s exact test test was used for statistical analysis.
Results:  69 of the 97 patients with CAD in the study group reached the primary end point whereas only 39 of 95 patients in the control group 
did.(p=0.0001)As to the patients without CAD 78of the 100 in the study group vs 52 in the control group acheived the primary point.(p=0.001).1 
Patient in each group discontinued their medicines due to elevated LFTs.There were 23 combined events in the CAD arm of control group over 4 
years vs 14 in the CAD arm of the study group.
Conclusion: The use of a novel patented expert system in lipid clinic significantly improves the laboratory and probably clinical outcomes of wide 
variety of patients with lipid disorders both for primary and secondary prevention purposes.
